ETF Data
XBI ETF Data
Fund Profile · Snapshot Metrics · Exposure · Technicals · Risk
XBI
ETF DataETF Data Overview
ETF pages show fund-native profile, cost, size, liquidity, exposure, technical, and risk evidence.
ETF Snapshot Data
Updated Sep 4, 2026.
| Field | Value |
|---|---|
| Fund name | State Street SPDR S&P Biotech ETF |
| Issuer | SPDR |
| Asset class | Equity |
| Primary exposure | Financial Services (0.40%) |
| Domicile | US |
| Inception date | Jan 31, 2006 |
| NAV currency | USD |
| CUSIP | 78464A870 |
| ISIN | US78464A8707 |
| Field | Value |
|---|---|
| Price | $163.81 |
| Fund size | $11.49B |
| Expense ratio | 0.35% |
| Holdings count | 154 |
| NAV | $164.46 |
| Average volume | 10.68M |
| Distribution yield | 0.57% |
| AIQ Score | 64/100 |
ETF Holdings
Reported holdings from the latest ETF holder snapshot.
| Symbol | Holding | Weight | Market value |
|---|---|---|---|
| MRNA | MODERNA INC | 2.98% | $342.82M |
| TWST | TWIST BIOSCIENCE CORP | 1.75% | $201.14M |
| HALO | HALOZYME THERAPEUTICS INC | 1.45% | $166.39M |
| NTRA | NATERA INC | 1.40% | $160.3M |
| KYMR | KYMERA THERAPEUTICS INC | 1.38% | $158.77M |
| PRAX | PRAXIS PRECISION MEDICINES I | 1.36% | $156.29M |
| RVMD | REVOLUTION MEDICINES INC | 1.35% | $154.87M |
| TVTX | TRAVERE THERAPEUTICS INC | 1.31% | $150.77M |
| ORKA | ORUKA THERAPEUTICS INC | 1.31% | $150.5M |
| DNTH | DIANTHUS THERAPEUTICS INC | 1.30% | $149.46M |
| PTGX | PROTAGONIST THERAPEUTICS INC | 1.30% | $148.99M |
| REGN | REGENERON PHARMACEUTICALS | 1.29% | $148.48M |
| INSM | INSMED INC | 1.27% | $146.02M |
| CGON | CG ONCOLOGY INC | 1.25% | $143.33M |
| PCVX | VAXCYTE INC | 1.24% | $142.63M |
| AMGN | AMGEN INC | 1.21% | $139.28M |
| SMMT | SUMMIT THERAPEUTICS INC | 1.18% | $135.8M |
| VRTX | VERTEX PHARMACEUTICALS INC | 1.18% | $135.61M |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | 1.17% | $134.47M |
| SRRK | SCHOLAR ROCK HOLDING CORP | 1.17% | $134.37M |
| GILD | GILEAD SCIENCES INC | 1.15% | $131.83M |
| VKTX | VIKING THERAPEUTICS INC | 1.13% | $129.68M |
| RYTM | RHYTHM PHARMACEUTICALS INC | 1.13% | $129.6M |
| ARWR | ARROWHEAD PHARMACEUTICALS IN | 1.13% | $129.5M |
| TGTX | TG THERAPEUTICS INC | 1.12% | $128.83M |
ETF Exposure
Sector and country composition fields from ETF snapshots where available.
| Field | Value |
|---|---|
| Financial Services | 0.40% |
| Healthcare | 99.60% |
| Field | Value |
|---|---|
| United States | 95.54% |
| United Kingdom | 1.12% |
| Switzerland | 1.05% |
| Netherlands | 1.00% |
| Ireland | 1.12% |
| Other | 0.18% |
Institutional Holder Snapshot
Latest downstream filing-reported holders and share-count changes for this ETF.
| Holder | Shares | Change | Reported |
|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 15.11M | 1.39M | Jun 30, 2026 |
| GOLDMAN SACHS GROUP INC | 15.11M | 1.39M | Jun 30, 2026 |
| TWO SIGMA INVESTMENTS, LP | 1.5M | 1.16M | Jun 30, 2026 |
| TWO SIGMA INVESTMENTS, LP | 1.5M | 1.16M | Jun 30, 2026 |
| CITIGROUP INC | 11.61M | 949.48K | Jun 30, 2026 |
| JPMORGAN CHASE & CO | 1.81M | -4.43M | Jun 30, 2026 |
| JPMORGAN CHASE & CO | 1.81M | -4.43M | Jun 30, 2026 |
| BNP PARIBAS ARBITRAGE, SNC | 16.78M | -4.38M | Jun 30, 2026 |
| BNP PARIBAS ARBITRAGE, SNC | 16.78M | -4.38M | Jun 30, 2026 |
| BANK OF AMERICA CORP /DE/ | 10.57M | -3.95M | Jun 30, 2026 |
Current ETF Metrics
ETF-native fields sit beside technical and risk readings for deeper research.
| Metric | Value | Unit | As of |
|---|---|---|---|
| Expense Ratio | 0.35 | percent | Sep 4, 2026 |
| Fund Size | 11,487,870,000 | currency | Sep 4, 2026 |
| Nav | 164.46 | currency_per_share | Sep 4, 2026 |
| Average Volume | 10,680,155 | count | Sep 4, 2026 |
| Distribution Yield | — | percent | Sep 4, 2026 |
| Beta | 1.1 | ratio | Sep 4, 2026 |
| High52 | — | currency_per_share | Sep 4, 2026 |
| Low52 | — | currency_per_share | Sep 4, 2026 |
| Metric | Value | Unit | As of |
|---|---|---|---|
| Close | 163.81 | price | Sep 4, 2026 |
| Volume | 3,811,699 | volume | Sep 4, 2026 |
| Rsi14 | 55.9 | index | Sep 4, 2026 |
| MACD | 2.67 | index | Sep 4, 2026 |
| MACD Signal | 3.14 | index | Sep 4, 2026 |
| MACD Histogram | -0.47 | index | Sep 4, 2026 |
| Adx14 | 21.37 | index | Sep 4, 2026 |
| Sma50 | 158.08 | price | Sep 4, 2026 |
| Sma200 | 135.37 | price | Sep 4, 2026 |
| Atr14 | 4.06 | price | Sep 4, 2026 |
| Historical Volatility | 0.32 | percent | Sep 4, 2026 |
| Volume Ma20 | 8,046,851.8 | volume | Sep 4, 2026 |
| Metric | Value | Unit | As of |
|---|---|---|---|
| Resilience Score | 59 | score_0_100 | Sep 4, 2026 |
| Beta | 1.1 | ratio | Sep 4, 2026 |
| Volatility Annual | 27.96 | percent | Sep 4, 2026 |
| Max Drawdown | -10.51 | percent | Sep 4, 2026 |
| Sharpe Ratio | 2.02 | ratio | Sep 4, 2026 |
| Var95 | -2.69 | percent | Sep 4, 2026 |
Additional ETF Metrics
Expanded ETF structure fields appear here when the entitlement and source coverage allow them.
No additional ETF structure metrics are available.
Related Links
XBI ETF Data FAQ
What is State Street SPDR S&P Biotech ETF's revenue?
State Street SPDR S&P Biotech ETF's revenue is one of the core financial data points for XBI. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.
Is State Street SPDR S&P Biotech ETF's revenue growing?
Revenue growth shows whether State Street SPDR S&P Biotech ETF is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.
What is XBI's EPS?
XBI's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.
What is State Street SPDR S&P Biotech ETF's net income?
State Street SPDR S&P Biotech ETF's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.
How much free cash flow does State Street SPDR S&P Biotech ETF generate?
Free cash flow shows how much cash State Street SPDR S&P Biotech ETF generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.
How much cash and debt does State Street SPDR S&P Biotech ETF have?
Cash and debt help frame XBI's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.